Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Bausch Health Companies Inc NPV

Sell:$22.90 Buy:$22.91 Change: $0.26 (1.12%)
Market closed |  Prices as at close on 17 July 2019 | Switch to live prices |
Sell:$22.90
Buy:$22.91
Change: $0.26 (1.12%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 17 July 2019 | Switch to live prices |
Sell:$22.90
Buy:$22.91
Change: $0.26 (1.12%)
Market closed |  Prices as at close on 17 July 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Contact details

Address:
2150 Saint-Elzear Blvd W
LAVAL
H7L 4A8
Canada
Telephone:
+1 (514) 7446792
Website:
https://www.bauschhealth.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
n/a
ISIN:
CA0717341071
Market cap:
$8.11 billion
Shares in issue:
351.88 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
Canada
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Papa
    Chairman of the Board, Chief Executive Officer
  • Paul Herendeen
    Chief Financial Officer, Executive Vice President
  • Thomas Appio
    President & Co-Head Bausch + Lomb/International
  • Joseph Gordon
    President & Co-Head Bausch + Lomb/International
  • William Humphries
    President of Ortho-Dermatologics
  • Mark McKenna
    President - Salix Pharmaceuticals
  • Christina Ackermann
    Executive Vice President, General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.